Oncology

Latest News

AJMC Q&A with Danny Nguyen, MD | Background image credit: ipopba - stock.adobe.com
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD

September 15th 2025

The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.

The use of miRNA in situ hybridization shows clear subtype-specific miRNAs, which the authors said warrant further investigation. | Image credit: CrazyJuke - stock.adobe.com
miRNA Profiling May Unlock SCLC Biomarkers

September 13th 2025

Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move
Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move

September 11th 2025

FDA | Image credit: Postmodern Studio.jpeg
FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors

September 10th 2025

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

September 8th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

leukemia word map | Image Credit: dizain-stock.adobe.com
Published: June 28th 2024 | Updated: June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
Ravi Parikh, MD, MPP, assistant professor of medicine and health policy, Perelman School of Medicine, University of Pennsylvania
June 27th 2024

Evaluating Palliative Care Impact: Insights From Tennessee Oncology's OCM Participation

Mary Caffrey Pearl Steinzor
A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.
Cancer health care concept-wladimir1804-stock.adobe.com.jpeg
June 26th 2024

NCCN Survey Reveals Best Practices for Managing Cancer Drug Shortage

Pearl Steinzor
The National Comprehensive Cancer Network (NCCN) survey finds 89% of centers continue to report shortages for at least one type of systemic therapy.
representation of targeted treatment | Image Credit: Kiattisak-stock.adobe.com
June 23rd 2024

Preclinical Study Shows Promise of Dual Targeted Treatment Against TNBC

AJMC Contributor
Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.
Interview with Jessica K. Paulus, ScD, Ontada
June 22nd 2024

Dr Jessica Paulus: Despite Treatment Advances, Progress in Lung Cancer Will Continue to Take Time

Maggie L. Shaw
“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”
Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
June 18th 2024

BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

Laura Joszt, MA
The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Ravin Ratan, MD, MEd, MD Anderson
June 18th 2024

Treating Sarcomas With Cutting-Edge Immune Checkpoint Blockade

Maggie L. Shaw
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas.
Tommy Pourmahram | Image credit: McKesson
June 17th 2024

Collaborative Solutions Are Needed to Address and Mitigate America’s Drug Shortages

Tommy Pourmahram
Drug costs | Image Credit: © Cagkan - stock.adobe.com
June 17th 2024

How Thyme Care Drives Reductions in Drug Spend in the Enhancing Oncology Model

Samyukta Mullangi, MD, MBA Robert Green, MD
sarcoma | Image Credit: Dzmitry-stock.adobe.com
June 15th 2024

Key MRI Features That Likely Correlate With STS Malignancy Grades

Maggie L. Shaw
Investigators from Germany conducted a systematic review of different MRI features in soft tissue sarcoma (STS) that are used to infer tumor histological grade.
FDA Approved
June 14th 2024

Repotrectinib Approved for Use in NTRK-Positive Solid Tumors

Julia Bonavitacola
Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option.
Human kidney cross section on scientific background | Crystal light - stock.adobe.com
June 13th 2024

Treatment-Free Survival Extended With Nivolumab/Cabozantinib in Advanced Renal Cell Carcinoma

Kyle Doherty
Nivolumab/cabozantinib combination therapy showed consistent benefits across various subgroups in patients with advanced renal cell carcinoma (RCC).
What We’re Reading: Federal Judge Blocks Florida Ban on Gender-Affirming Care; NASEM Releases Definition for Long COVID; NIH Pilot Fails to Diversify Cancer Research
June 12th 2024

What We’re Reading: Florida Ban on Gender-Affirming Care Blocked; Definition for Long COVID; NIH Pilot Fails to Diversify Cancer Research

AJMC Staff
Judge rules Florida's ban on gender-affirming care for minors unconstitutional; first consensus definition for long COVID aims to standardize diagnosis and care; pilot program for clinical trial diversity discontinued due to high cost and lack of impact.
mily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center
June 11th 2024

Dr Emily Touloukian: The Power of Patient Advocacy in Community Oncology

Maggie L. Shaw Pearl Steinzor
Emily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center, discusses the importance of patient advocacy when it comes to current issues such as drug shortages and mail order restrictions.
Antibody drug conjugate in blue | huenstructurebio.com - stock.adobe.com
June 5th 2024

Antibody Drug Conjugates Show Promise in Biomarker, Prognostic Outcomes in Oncology Care

Pearl Steinzor
Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.
Neal Shore, MD, FACS, an expert on bladder cancer
May 29th 2024

Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Neal Shore, MD, FACS, an expert on bladder cancer
May 29th 2024

NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Neal Shore, MD
Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.
Enhertu packaging | Image credit: AstraZeneca
May 29th 2024

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers

Ryan Flinn
Aiwu Ruth He, MD, PhD | Image credit: Medstar Health
May 27th 2024

Aiwu Ruth He, MD, PhD, Discusses 3-Year Survival Data for Durvalumab Plus Chemo in Biliary Tract Cancer, Other Advances

Interview by Mary Caffrey
what we're reading logo
May 24th 2024

What We’re Reading: Bird Flu Protective Gear; HPV Vaccine Protects Against Head, Neck Cancers; Tobacco Industry and Vapes

AJMC Staff
Many US dairy farms have not yet increased bird flu protections for employees despite the outbreak in cows; the human papillomavirus (HPV) vaccine is linked to a drastic reduction in head and neck cancers in adolescent boys and men; the World Health Organization recently accused tobacco companies of actively trying to hook a new generation on nicotine.
Natalie Dickson, MD, MMHC, FASCO, FACP | Image credit: Tennessee Oncology
May 20th 2024

Natalie Dickson, MD, MMHC, FASCO, FACP, of Tennessee Oncology Discusses Cutting-Edge Cancer Care Initiatives

Maggie L. Shaw
AHN logo | Image credit: Allegheny Health Network
May 20th 2024

AHN Cancer Institute Raises the Quality and Value Bar by Listening to Patients

Mary Caffrey
Stephen Schleicher, MD, MBA | Image credit: Tennessee Oncology
May 20th 2024

At Hearing on Recurring Cancer Drug Shortages, Rural Areas Come Into Focus

Peter Page
Bobby Reddy, MD | Image credit: Keri Tan
Published: May 20th 2024 | Updated: May 20th 2024

“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials

Mary Caffrey
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
May 14th 2024

Dr Mila Felder Discusses Promoting Well-Being Within an Organization

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.
Doctor talking to patient about prostate cancer | Image credit: kenchiro168 – stock.adobe.com
May 13th 2024

IMPLEMENT Study Finds Gaps in How Urologists, Oncologist View First-Line Treatment Intensification for Prostate Cancer

Hayden E. Klein
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
what we're reading logo
May 8th 2024

What We’re Reading: Rural Health Clinic Accreditation; Cancer Mortality in Black Women; COVID-19 Vaccination Campaign Savings

AJMC Staff
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
AJMC
May 6th 2024

Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America

Pankaj Kumar, MD Stephanie Parker, PharmD DeShawn Wilbern, MBA
CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
COA ADVOCACY PANEL | Image credit: COA
April 25th 2024

Galvanizing Community Oncology Through Advocacy, Empowerment, and Stewardship

Maggie L. Shaw
Coverage from the Community Oncology Alliance Community Oncology Conference, held April 4-5, 2024, in Orlando, Florida.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 25th 2024

Dr Mila Felder: Supporting Well-Being in Oncology Care Using Surveys

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses various surveys deployed within Advocate Health to promote organizational well-being.
<1
...
789101112131415
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo